Immunovant (IMVT) total liabilities

Total liabilities · fiscal 2026
$104.42M

Immunovant (IMVT) had total liabilities of $104.42M at the end of fiscal 2026 (March 31, 2026). That is 51.8% higher than the $68.78M of fiscal 2025. Figures as of 19 Nov 2026, 00:41 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2026
$104.42M
Change on fiscal 2025
+51.8%
Growth, 5 years
+37.8% a year
Highest on record
$104.42Mfiscal 2026
Lowest on record
$6.49Mfiscal 2019
Fiscal years on record
82019–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Immunovant total liabilities, in more detail

Over the five fiscal years to 2026 total liabilities grew at a compound 37.8% a year. Across the 8 fiscal years on record (2019–2026), the highest was $104.42M in fiscal 2026 and the lowest $6.49M in fiscal 2019.

History · 8 fiscal years

Total liabilities by fiscal year

Immunovant total liabilities, year by year

Immunovant (IMVT) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2026$104.42M 51.8% up
2025$68.78M 41.5% up
2024$48.61M 12.1% up
2023$43.34M 5.2% down
2022$45.74M 117.7% up
2021$21.01M 37.2% up
2020$15.32M 136.1% up
2019$6.49M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Immunovant and comparable companies
CompanyTotal liabilitiesFiscal year
Immunovant IMVT$104.42M2026
Axsome Therapeutics AXSM$601.51M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on IMVT

Immunovant, figure by figure

Immunovant (IMVT) overview: price, valuation and scorecardAll health care companies by market value

Immunovant total liabilities: questions and answers

How large are Immunovant's total liabilities?

Immunovant (IMVT) had total liabilities of $104.42M at the end of fiscal 2026 (March 31, 2026). That is 51.8% higher than the $68.78M of fiscal 2025.

What is the growth rate of Immunovant's total liabilities?

Over the five fiscal years to 2026 total liabilities grew at a compound 37.8% a year.

What are the highest and lowest total liabilities figures on record for Immunovant?

Across the 8 fiscal years on record (2019–2026), the highest was $104.42M in fiscal 2026 and the lowest $6.49M in fiscal 2019.

How is Immunovant's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Immunovant it is on record here for 8 fiscal years, 2019 to 2026.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Immunovant (IMVT) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/IMVT/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.